Takeda Pharmaceutical Co. Ltd. Sponsored ADR (TSE:4502) is advancing oral TYK2 inhibitor zasocitinib toward a U.S. launch in H1 2027 after strong Phase III psoriasis PASI-100 results versus deucravacitinib, while Q1 FY2026 revenue rose and full-year guidance was reaffirmed despite lower core EPS and pending Phase II IBD readouts.
Previous Week Recap
- Takeda Pharmaceutical Co. Ltd. Sponsored ADR: TYK2 Inhibitor Phase III Psoriasis: Takeda (4502): oral TYK2 inhibitor zasocitinib targets U.S. launch H1 2027. Phase III psoriasis: >35% achieved PASI-100 at week 16 versus deucravacitinib. Phase II IBD data due by FY2026 end.
- Takeda Pharmaceutical Co. Ltd. Sponsored ADR: Q1 FY2026 Revenue Rise: Takeda (4502) Q1 FY2026: revenue up 10.2% on actual FX, flat on constant currency; core EPS fell vs. prior year due to one-time tax items; full-year FY2026 guidance reaffirmed.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.